Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 203

1.

Risk factors for invasive pneumococcal disease in children in the era of conjugate vaccine use.

Pilishvili T, Zell ER, Farley MM, Schaffner W, Lynfield R, Nyquist AC, Vazquez M, Bennett NM, Reingold A, Thomas A, Jackson D, Schuchat A, Whitney CG.

Pediatrics. 2010 Jul;126(1):e9-17. doi: 10.1542/peds.2009-2150. Epub 2010 Jun 14.

PMID:
20547641
2.

Recommendations for the prevention of Streptococcus pneumoniae infections in infants and children: use of 13-valent pneumococcal conjugate vaccine (PCV13) and pneumococcal polysaccharide vaccine (PPSV23).

American Academy of Pediatrics Committee on Infectious Diseases.

Pediatrics. 2010 Jul;126(1):186-90. doi: 10.1542/peds.2010-1280. Epub 2010 May 24.

PMID:
20498180
3.

Population-based surveillance for childhood invasive pneumococcal disease in the era of conjugate vaccine.

Hsu K, Pelton S, Karumuri S, Heisey-Grove D, Klein J; Massachusetts Department of Public Health Epidemiologists.

Pediatr Infect Dis J. 2005 Jan;24(1):17-23.

PMID:
15665705
4.

Changing epidemiology of invasive pneumococcal disease among White Mountain Apache persons in the era of the pneumococcal conjugate vaccine.

Lacapa R, Bliss SJ, Larzelere-Hinton F, Eagle KJ, McGinty DJ, Parkinson AJ, Santosham M, Craig MJ, O'Brien KL.

Clin Infect Dis. 2008 Aug 15;47(4):476-84. doi: 10.1086/590001.

PMID:
18627249
5.

Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction--eight states, 1998-2005.

Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 2008 Feb 15;57(6):144-8.

6.

Effectiveness of the 7-valent pneumococcal conjugate vaccine: a population-based case-control study.

Barricarte A, Castilla J, Gil-Setas A, Torroba L, Navarro-Alonso JA, Irisarri F, Arriazu M.

Clin Infect Dis. 2007 Jun 1;44(11):1436-41. Epub 2007 Apr 16.

PMID:
17479939
7.

Surveillance for invasive pneumococcal disease during 2000-2005 in a population of children who received 7-valent pneumococcal conjugate vaccine.

Black S, France EK, Isaacman D, Bracken L, Lewis E, Hansen J, Fireman B, Austrian R, Graepel J, Gray S, Klein NP.

Pediatr Infect Dis J. 2007 Sep;26(9):771-7.

PMID:
17721369
8.

Temporal trends of invasive disease due to Streptococcus pneumoniae among children in the intermountain west: emergence of nonvaccine serogroups.

Byington CL, Samore MH, Stoddard GJ, Barlow S, Daly J, Korgenski K, Firth S, Glover D, Jensen J, Mason EO, Shutt CK, Pavia AT.

Clin Infect Dis. 2005 Jul 1;41(1):21-9. Epub 2005 May 26.

PMID:
15937758
9.

Changing serotypes causing childhood invasive pneumococcal disease: Massachusetts, 2001-2007.

Hsu KK, Shea KM, Stevenson AE, Pelton SI; Massachusetts Department of Public Health.

Pediatr Infect Dis J. 2010 Apr;29(4):289-93. doi: 10.1097/INF.0b013e3181c15471.

PMID:
19935447
11.

Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine.

Pilishvili T, Lexau C, Farley MM, Hadler J, Harrison LH, Bennett NM, Reingold A, Thomas A, Schaffner W, Craig AS, Smith PJ, Beall BW, Whitney CG, Moore MR; Active Bacterial Core Surveillance/Emerging Infections Program Network.

J Infect Dis. 2010 Jan 1;201(1):32-41. doi: 10.1086/648593.

PMID:
19947881
12.

Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001.

Bisgard KM, Rhodes P, Connelly BL, Bi D, Hahn C, Patrick S, Glodé MP, Ehresmann KR; Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA. kbisgard@cdc.gov.

Pediatrics. 2005 Aug;116(2):e285-94.

PMID:
16061582
13.

Invasive pneumococcal disease in young children before licensure of 13-valent pneumococcal conjugate vaccine - United States, 2007.

Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 2010 Mar 12;59(9):253-7.

14.

Use of surveillance data to estimate the effectiveness of the 7-valent conjugate pneumococcal vaccine in children less than 5 years of age over a 9 year period.

De Serres G, Pilishvili T, Link-Gelles R, Reingold A, Gershman K, Petit S, Farley MM, Harrison LH, Lynfield R, Bennett NM, Baumbach J, Thomas A, Schaffner W, Beall B, Whitney C, Moore M.

Vaccine. 2012 Jun 8;30(27):4067-72. doi: 10.1016/j.vaccine.2012.04.017. Epub 2012 Apr 21.

PMID:
22525797
15.

Changing characteristics of invasive pneumococcal disease in Metropolitan Atlanta, Georgia, after introduction of a 7-valent pneumococcal conjugate vaccine.

Albrich WC, Baughman W, Schmotzer B, Farley MM.

Clin Infect Dis. 2007 Jun 15;44(12):1569-76. Epub 2007 May 8.

PMID:
17516400
16.

Invasive pneumococcal disease a decade after pneumococcal conjugate vaccine use in an American Indian population at high risk for disease.

Weatherholtz R, Millar EV, Moulton LH, Reid R, Rudolph K, Santosham M, O'Brien KL.

Clin Infect Dis. 2010 May 1;50(9):1238-46. doi: 10.1086/651680.

PMID:
20367225
17.
18.

Indirect effect of 7-valent pneumococcal conjugate vaccine on pneumococcal colonization among unvaccinated household members.

Millar EV, Watt JP, Bronsdon MA, Dallas J, Reid R, Santosham M, O'Brien KL.

Clin Infect Dis. 2008 Oct 15;47(8):989-96. doi: 10.1086/591966.

PMID:
18781875
19.

[Epidemiological features of invasive pneumococcal disease before and after the introduction of pneumococcal conjugate vaccine in Gran Canaria (Canary Islands)].

Artiles F, Horcajada I, Cañas AM, Alamo I, Bordes A, González A, Santana M, Lafarga B.

Enferm Infecc Microbiol Clin. 2009 Jan;27(1):14-21. doi: 10.1016/j.eimc.2008.03.001. Epub 2009 Jan 9. Spanish.

PMID:
19217998
20.

Invasive pneumococcal disease in Alaskan children: impact of the seven-valent pneumococcal conjugate vaccine and the role of water supply.

Wenger JD, Zulz T, Bruden D, Singleton R, Bruce MG, Bulkow L, Parks D, Rudolph K, Hurlburt D, Ritter T, Klejka J, Hennessy T.

Pediatr Infect Dis J. 2010 Mar;29(3):251-6. doi: 10.1097/INF.0b013e3181bdbed5.

PMID:
19952861

Supplemental Content

Support Center